Highest-materiality recent filing
Certara Q1 revenue $106.9M (+1%), net loss $8.8M; divests Regulatory Writing for $85M cash
Revenue $106.9M (+1% YoY); software revenue $49.7M (+7%), services revenue $57.2M (-4%).
Certara sells Regulatory & Medical Writing business to Veristat for up to $135M
Cash consideration of $100M plus up to $35M earn-out based on future performance.
Certara Q4 revenue $103.6M (+3%), net loss $5.9M; appoints Jon Resnick CEO; FY26 rev growth 0-4%
Q4 2025 revenue $103.6M (+3% YoY); software revenue $46.4M (+10%), services $57.3M (-1%).
Certara appoints Jon Resnick as CEO effective Jan 1, 2026; Feehery departs Dec 31
Jon Resnick, former IQVIA US/Canada President, named CEO effective Jan 1, 2026; William Feehery steps down Dec 31, 2025.
Certara Q3 2025 revenue $104.6M (+10% YoY); net income $1.5M vs loss; guidance raised
Revenue $104.6M, +10% YoY; software $43.8M (+22%), services $60.8M (+3%).
Certara Q2 2025 revenue $104.6M (+12% YoY); net loss narrows to $2.0M; reiterates FY guidance
Revenue $104.6M (+12% YoY); software revenue $46.7M (+22%), services $57.9M (+5%).
Certara Q1 2025 revenue up 10% to $106M; net income positive vs year-ago loss
Revenue $106.0M (+10% YoY); software rev $46.4M (+18%), services $59.6M (+4%).
Certara reports Q1 preliminary revenue up 10% to $106M; $100M buyback authorized
Preliminary Q1 revenue $106.0M (+10% YoY); software revenue $46.4M (+18%), services $59.6M (+4%).
Certara Q4 revenue +14% to $100.4M; net income turns positive; guides 2025 margins
Q4 revenue $100.4M (+14% YoY); software rev $42.3M (+26%), services $58.1M (+7%).
Certara reports preliminary Q4 revenue $99.7M (+13% YoY); FY revenue $384.4M (+8%)
Q4 revenue $99.7M vs $88.0M YoY; software +24% to $41.6M, services +7% to $58.1M.
Certara Q3 rev $94.8M (+11% YoY); net loss narrows to $1.4M; guides FY24
Revenue $94.8M (+11% YoY); software rev $35.9M (+15%), services rev $58.9M (+9%).
Certara signs definitive agreement to acquire Chemaxon; reiterates 2024 guidance
Definitive agreement to acquire Chemaxon, a cheminformatics software provider; no deal value disclosed.
Certara refinances credit facility; extends term loan maturity to 2031, revolver to 2029
Total new term loans of $300M (including $5M incremental) refinance existing debt and fund general corporate purposes.
Certara Q1 revenue $96.7M +7% YoY; net loss $4.7M, reiterates FY guidance
Revenue $96.7M (+7% YoY); software rev $39.3M (+19%), services $57.3M (flat).
On March 5, 2025, Certara, Inc. (the “Company”) announced that Dr. Patrick F. Smith, President, Certara Drug Development Solutions, stepped down from that role as of March 3, 2025, but will remain employed by the Company in a senior advisory and scientific role.
On October 16, 2024, the Board of Directors (the “Board”) of Certara, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, voted to appoint Dr. John V. W. Reynders as a Class II director of the Board and a member of the Audit Committee of the Board, effective immediately.
Max materiality 0.75 · Median 0.65 · Most common event earnings